Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation

Translational Oncology

Volumn 2, Issue 4, 2009, Pages 329-340

  Ricca, Tatiana I ^a   Liang, Gangning ^b   Suenaga, Ana Paula M ^a   Han, Sang W ^a   Jones, Peter A ^b   Jasiulionis, Miriam G ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANOIKIS; ARTICLE; C57BL 6 MOUSE; CANCER CELL CULTURE; CARCINOGENESIS; CELL SURVIVAL; DNA METHYLATION; FEMALE; GENETIC TRANSFECTION; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA CELL; MOUSE; NONHUMAN; PLASMID; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING;

EID: 77953424645     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09220     Document Type: Article

References (74)

1. Sepulveda JL, Gkretsi V, and Wu C (2005). Assembly and signaling of adhesion complexes. Curr Top Dev Biol 68, 183-225.
2. Giancotti FG and Ruoslahti E (1999). Integrin signaling. Science 285, 1028-1032.
3. Frisch SM and Francis H (1994). Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124, 619-626.
4. Díaz-Montero CM and McIntyre BW (2003). Acquisition of anoikis resistance in human osteosarcoma cells. Eur J Cancer 39, 2395-2402.
5. Grossmann J (2002). Molecular mechanisms of "detachment-induced apoptosis-anoikis". Apoptosis 7, 247-260.
6. Zhu Z, Sanchez-Sweatman O, Huang X, Wiltrout R, Khokha R, Zhao Q, and Gorelik E (2001). Anoikis and metastatic potential of Cloudman S91 melanoma cells. Cancer Res 61, 1707-1716.
7. Chiarugi P and Giannoni E (2008). Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 76, 1352-1364.
8. Nagase H and Woessner JF Jr (1999). Matrix metalloproteinases. J Biol Chem 274, 21491-21494.
9. Lambert E, Dassé E, Haye B, and Petitfrère E (2004). TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49, 187-198.
10. McCarthy K,Maguire T,McGreal G,McDermott E, O'Higgins N, and Duffy MJ (1999). High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 84, 44-48.
11. Murashige M, Miyahara M, Shiraishi N, Saito T, Kohno K, and Kobayashi M (1996). Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol 26, 303-309.
12. Chirco R, Liu XW, Jung KK, and Kim HR (2006). Novel functions of Timps in cell signaling. Cancer Metastasis Rev 25, 99-113.
13. Li G, Fridman R, and Kim HR (1999). Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59, 6267-6275.
14. Jung KK, Liu XW, Chirco R, Fridman R, and Kim HR (2006). Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 25, 3934-3942.
15. Miranda TB and Jones PA (2007). DNA methylation: the nuts and bolts of repression. J Cell Physiol 213, 384-390.
16. Huang X, Orucevic A, Li M, and Gorelik E (2000). Nitric oxide NO, methylation and TIMP-1 expression in BL6 melanoma cells transfected with MHC class I genes. Clin Exp Metastasis 18, 329-335.
17. Oba-Shinjo SM, Correa M, Ricca TI, Molognoni F, Pinhal MA, Neves IA, Marie SK, Sampaio LO, Nader HB, Chammas R, et al. (2006). Melanocyte transformation associated with substrate adhesion impediment. Neoplasia 8, 231-241.
18. Bennett DC, Cooper PJ, and Hart IR (1987). A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 39, 414-418.
19. Mosmann T (1983). Rapid colorimetric assay for growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63.
20. Gonzalgo ML and Jones PA (2002). Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension Ms-SNuPE. Methods 27, 128-133.
21. FrommerM,McDonald LE,Millar DS, CollisCM,Watt F, Grigg GW,Molloy PL, and Paul CL (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individualDNAstrands. Proc Natl Acad Sci USA 89, 1827-1831.
22. Supiot S, Gouard S, Charrier J, Apostolidis C, Chatal JF, Barbet J, Davodeau F, and Cherel M (2005). Mechanisms of cell sensitization to a radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 11, 7047s-7052s.
23. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Gosh D, Barrette T, Pandey A, and Chinnaiyan AM (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6.
24. Rhee JS, Diaz R, Korets L, Hodgson JG, and Coussens LM (2004). TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 64, 952-961.
25. Hawthorn L, Stein L, Varma R, Wiseman S, Lorre T, and Tan D (2004). TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head Neck 26, 1069-1083.
26. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, and Wang Y (2005). Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11, 7234-7242.
27. Campos ACE, Molognoni F, Melo FH, Galdieri LC, Carneiro CR, D'Almeida V, Correa M, and Jasiulionis MG (2007). Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. Neoplasia 9, 1111-1121.
28. Frisch SM (1994). E1a induces the expression of epithelial characteristics. J Cell Biol 127, 1085-1096.
29. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, Wagner SN, Ramaswamy S, Mesirov JP, and Hynes RO (2008). Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 6, 760-769.
30. Chin SF, Teschendorff AE,Marioni JC,Wang Y, Barbosa-Morais NL, Thorne NP, Costa JL, Pinder SE, van de Wiel MA, Green AR, et al. (2007). High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 8, R215.
31. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357.
32. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511.
33. Storz MN, van de Rijn M, Kim YH, Mraz-Gernhard S, Hoppe RT, and Kohler S (2003). Gene expression profiles of cutaneous B cell lymphoma. J Invest Dermatol 120, 865-870.
34. Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, Lee WS, Kim NK, Chung HC, and Rha SY (2007). Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 121, 2005-2012.
35. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Grémy G, Couillault C, Lajémi M, Piatier-Tonneau D, Zaborski P, et al. (2006). Deciphering cellular states of innate tumor drug responses. Genome Biol 7, R19.
36. Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, Foekens JA, Brunner N, and Holten-Andersen MN (2003). Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 TIMP-1 and plasminogen activator inhibitor type 1 PAI-1 are complementary in determining prognosis in primary breast cancer.Mol Cell Proteomics 2, 164-172.
37. Kossakowska AE, Urbanski SJ, and Edwards DR (1991). Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood 77, 2475-2481.
38. Yoshino Y, Kageshita T, Nakajima M, Funakubo M, and Ihn H (2008). Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma. J Dermatol 35, 206-214.
39. Grossmann J, Walther K, Artinger M, Kiessling S, and Schölmerich J (2001). Apoptotic signaling during initiation of detachment-induced apoptosis ("anoikis") of primary human intestinal epithelial cells. Cell Growth Differ 12, 147-155.
40. Freedman VH and Shin SI (1974). Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3, 355-359.
41. Rak J,Mitsuhashi Y, Sheehan C, Krestow JK, Florenes VA, Filmus J, and Kerbel RS (1999). Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis. Neoplasia 1, 23-30.
42. Meredith JE Jr and Schwartz MA (1997). Integrins, adhesion and apoptosis. Trends Cell Biol 7, 146-150.
43. Elezkurtaj S, Kopitz C, Baker AH, Perez-Cantó A, Arlt MJ, Khokha R, Gansbacher B, Anton M, Brand K, and Krüger A (2004). Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis. J Gene Med 6, 1228-1237.
44. Yamauchi K, Ogata Y, Nagase H, and Shirouzu K (2001). Inhibition of liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP-1 gene into KM12SM cells. Surg Today 31, 791-798.
45. Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, Tsujinoue H, Yanase K, NamisakiT, ImazuH,MasakiT, et al. (2003).Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 105, 340-346.
46. Yamazaki M, Akahane T, Buck T, Yoshiji H, Gomez DE, Schoeffner DJ, Okajima E, Harris SR, Bunce OR, Thorgeirsson SS, et al. (2004). Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice. Carcinogenesis 25, 1735-1746.
47. De Lorenzo MS, Ripoll GV, Yoshiji H, Yamazaki M, Thorgeirsson UP, Alonso DF, and Gomez DE (2003). Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In Vivo 17, 45-50.
48. Shi Y, Parhar RS, ZouM, Al-Mohanna FA, and PatersonMC (2002). Gene therapy of melanoma pulmonary metastasis by intramuscular injection of plasmid DNA encoding tissue inhibitor of metalloproteinases-1. Cancer Gene Ther 9, 126-132.
49. Khokha R (1994). Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 86, 299-304.
50. Xu F, Carlos T, Li M, Sanchez-Sweatman O, Khokha R, and Gorelik E (1998). Inhibition of VLA-4 and up-regulation of TIMP-1 expression in B16BL6 melanoma cells transfected with MHC class I genes. Clin Exp Metastasis 16, 358-370.
51. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi AL, Keski-Oja J, and Saarialho-Kere UK (1999). Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 80, 733-743.
52. MacDougall JR, Bani MR, Lin Y,Muschel RJ, and Kerbel RS (1999). "Proteolytic switching": opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer 80, 504-512.
53. Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ, Hauser S, Flechsig C, Krell HW, Antolovic D, Brew K, et al. (2007). Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 67, 8615-8623.
54. Goss KJ, Brown PD, and Matrisian LM (1998). Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 78, 629-635.
55. Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, and Stetler-Stevenson WG (2001). Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 158, 1207-1215.
56. Kopitz C, Gerg M, Gansbacher B, and Krüger A (2008). Plasminogen activator inhibitor-2 but not cystatin C inhibits the pro-metastatic activity of tissue inhibitor of metalloproteinases-1 in the liver. Hum Gene Ther 19, 1039-1049.
57. Aljada IS, Ramnath N, Donohue K, Harvey S, Brooks JJ, Wiseman SM, Khoury T, Loewen G, Slocum HK, Anderson TM, et al. (2004). Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol 22, 3218-3229.
58. Hoashi T, Kadono T, Kikuchi K, Etoh T, and Tamaki K (2001). Differential growth regulation in human melanoma cell lines by TIMP-1 andTIMP-2. Biochem Biophys Res Commun 288, 371-379.
59. Egeblad M and Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174.
60. Heppner KJ, Matrisian LM, Jensen RA, and Rodgers WH (1996). Expression of most matrix metalloproteinase family members in breast cancer represents a tumorinduced host response. Am J Pathol 149, 273-282.
61. Baker EA, Bergin FG, and Leaper DJ (2000). Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 87, 1215-1221.
62. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, and Noguchi Y (2001). Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma a new biomarker for invasion and its impact on survival. Cancer 91, 1739-1744.
63. Würtz S∅, Schrohl AS,Mouridsen H, and Brünner N (2008). TIMP-1 as a tumor marker in breast cancer-an update. Acta Oncol 47, 580-590.
64. Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, Hamer P, Brown-Shimer S, Pierce K, Gaur V, et al. (2008). Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol 26, 2653-2658.
65. Laird PW (2005). Cancer epigenetics. Hum Mol Genet 14, R65-R76.
66. Gopisetty G, Ramachandran K, and Singal R (2006). DNA methylation and apoptosis. Mol Immunol 43, 1729-1740.
67. Jones PA and Baylin SB (2007). The epigenomics of cancer. Cell 128, 683-692.
68. Eckhardt F, Lewin Cortese R, Rakyan VK, Attwood J, Burger M, Burton J, Cox TV, Davies R, Down TA, Haefliger C, et al. (2006). DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 3812, 1378-1385.
69. Bruniquel D and Schwartz RH (2003). Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 4, 235-240.
70. Wada K, Maesawa C, Akasaka T, and Masuda T (2004). Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J Invest Dermatol 122, 805-811.
71. Mehlen P and Puisieux A (2006). Metastasis: a question of life or death. Nat Rev Cancer 6, 449-458.
72. Zucker S, Cao J, and Chen WT (2000). Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642-6650.
73. Coussens LM, Fingleton B, and Matrisian LM (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392.
74. Stetler-Stevenson WG (2008). Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1, re6.